ArticleThe journal of headache and pain2015
Cost-effectiveness of stimulation of the sphenopalatine ganglion (SPG) for the treatment of chronic cluster headache: a model-based analysis based on the Pathway CH-1 study.
Article in The journal of headache and pain, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Noninvasive Vagus Nerve Stimulation for Cluster Headache and Migraine: A Health Technology Assessment.Ontario health technology assessment series · 2025Pooled it
- Sphenopalatine Ganglion Blocks in Headache Management: A Review.Brain sciences · 2025Review
- Consensus Guidelines for the Use of Peripheral Nerve Stimulation in the Treatment of Chronic Pain and Neurological Diseases: A Neuron Project from the American Society of Pain and Neuroscience.Journal of pain research · 2025Article
- Neuromodulation for the Sphenopalatine Ganglion-a Narrative Review.Current pain and headache reports · 2023Review
- Debate: Are cluster headache and migraine distinct headache disorders?The journal of headache and pain · 2022Review
- gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance.PharmacoEconomics - open · 2021Review
- [Pain physicians should not turn a blind eye: what happens when a medical product manufacturer ceases providing equipment?]Schmerz (Berlin, Germany) · 2020Article
- Sphenopalatine Ganglion Block and Radiofrequency Ablation: Technical Notes and Efficacy.Ochsner journal · 2019Review
- Sphenopalatine ganglion stimulation for cluster headache, results from a large, open-label European registry.The journal of headache and pain · 2018Article
- Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache.Cephalalgia : an international journal of headache · 2017Article
- Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache.The journal of headache and pain · 2016Article
- Cluster headache: a quasi-rare disorder needing a reappraisal.The journal of headache and pain · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the recent Pathway CH-1 study, on-demand stimulation of the sphenopalatine ganglion (SPG) by means of an implantable neurostimulation system was proven to be a safe and effective therapy for the treatment of chronic cluster headache. Our objective was to assess the cost-effectiveness of SPG stimulation in the German healthcare system when compared to medical management.
methodsClinical data from the Pathway CH-1 study were used as input for a model-based projection of the cost-effectiveness of SPG stimulation through 5 years. Medical management as the comparator treatment was modeled on the basis of clinical events observed during the baseline period of CH-1. The costs of treatment were derived from a previously published cluster headache costing study and 2014 medication, neurostimulator, and procedure costs. We computed the 5-year incremental cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY), with costs and effects discounted at 3 % per year.
resultsSPG stimulation was projected to add 0.325 QALYs over the study period, while adding €889 in cost, resulting in a 5-year ICER of €2,736 per QALY gained. Longer follow-up periods, higher baseline attack frequency, and higher utilization of attack-aborting medications led to overall cost savings. SPG stimulation was found either cost-effective or cost-saving across all scenarios investigated in sensitivity analyses.
conclusionsOur model-based analysis suggests that SPG stimulation for the treatment of chronic cluster headache, under the assumption of sustained therapy effectiveness, leads to meaningful gains in health-related quality of life and is a cost-effective treatment strategy in the German healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.